These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 22785335

  • 1. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
    Rajendran R, Grossman AB, Kar P.
    Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
    [Abstract] [Full Text] [Related]

  • 2. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM.
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [Abstract] [Full Text] [Related]

  • 3. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA, Cranston IC.
    BMC Endocr Disord; 2017 Nov 06; 17(1):69. PubMed ID: 29110656
    [Abstract] [Full Text] [Related]

  • 4. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Pose-Reino A, Runkle de la Vega I, de Jong-Laird A, Kabra M, Lindner U.
    Adv Ther; 2021 Feb 06; 38(2):1055-1067. PubMed ID: 33306187
    [Abstract] [Full Text] [Related]

  • 5. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 06; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 06; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis and management of hyponatraemia in the older patient.
    Woodward M, Gonski P, Grossmann M, Obeid J, Scholes R, Topliss DJ.
    Intern Med J; 2018 Jan 06; 48 Suppl 1():5-12. PubMed ID: 29318728
    [Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW, Yi JH, Kang KP, Kim HY, Kim SW, Choi HY, Ha SK, Kim GH, Kim YW, Jeong KH, Shin SK, Kim HJ.
    J Korean Med Sci; 2018 Apr 09; 33(15):e112. PubMed ID: 29629516
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C, Robinson P, O'Reilly K, Lundberg J, Gisby M, Ländin M, Skov J, Trueman D.
    BMC Endocr Disord; 2016 May 16; 16(1):22. PubMed ID: 27184496
    [Abstract] [Full Text] [Related]

  • 10. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A, McCormick L, Rahman M.
    Adv Ther; 2021 Dec 16; 38(12):5721-5736. PubMed ID: 34693505
    [Abstract] [Full Text] [Related]

  • 11. Tolvaptan.
    Plosker GL.
    Drugs; 2010 Mar 05; 70(4):443-54. PubMed ID: 20205486
    [Abstract] [Full Text] [Related]

  • 12. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
    Velez JC, Dopson SJ, Sanders DS, Delay TA, Arthur JM.
    Nephrol Dial Transplant; 2010 May 05; 25(5):1524-31. PubMed ID: 20064953
    [Abstract] [Full Text] [Related]

  • 13. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial.
    Warren AM, Grossmann M, Hoermann R, Zajac JD, Russell N.
    Trials; 2022 Apr 21; 23(1):335. PubMed ID: 35449020
    [Abstract] [Full Text] [Related]

  • 14. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 21; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 15. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 16. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
    Tzoulis P, Carr H, Bagkeris E, Bouloux PM.
    Endocrine; 2017 Feb 16; 55(2):539-546. PubMed ID: 27837439
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D, Milford DV, Bandhakavi M, Van't Hoff W, Kleta R, Dattani M, Bockenhauer D.
    Acta Paediatr; 2016 Jul 16; 105(7):e334-7. PubMed ID: 27028950
    [Abstract] [Full Text] [Related]

  • 18. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP, DeVita MV, Michelis MF.
    Int Urol Nephrol; 2012 Jun 16; 44(3):865-71. PubMed ID: 21607553
    [Abstract] [Full Text] [Related]

  • 19. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
    Petereit C, Zaba O, Teber I, Lüders H, Grohé C.
    BMC Pulm Med; 2013 Aug 29; 13():55. PubMed ID: 23987478
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 29; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.